论文部分内容阅读
目的探讨奥扎格雷钠应用于急性脑梗死治疗的临床效果。方法 102例确诊为急性脑梗死患者,随机分为对照组与观察组,各51例。对照组给予20 ml丹参注射液+150 ml 5%葡萄糖溶液,观察组给予80 ml奥扎格雷钠+100 ml 0.9%氯化钠溶液。以两组患者治疗效果、治疗前后神经功能缺损情况、治疗前后患者的血液流变学指标(凝血酶原时间、纤维蛋白原)为观察指标,评估奥扎格雷钠的临床疗效。结果观察组患者治疗总有效率为96.08%,明显高于对照组的84.31%,差异有统计学意义(P<0.05)。两组治疗前凝血酶原时间、纤维蛋白原水平、神经功能缺评分比较差异无统计学意义(P>0.05)。治疗后两组凝血酶原时间均长于治疗前、纤维蛋白原水平低于治疗前、神经功能缺评分低于治疗前,差异均有统计学意义(P<0.05);且观察组变化较对照组更为显著,差异均有统计学意义(P<0.05)。结论奥扎雷格钠治疗急性脑梗死的临床效果较好,能有效改善患者的血液流变学及神经功能,有益于患者预后。
Objective To investigate the clinical effect of ozagrel sodium in the treatment of acute cerebral infarction. Methods A total of 102 patients diagnosed as acute cerebral infarction were randomly divided into control group and observation group, with 51 cases in each group. The control group was given 20 ml salvia miltiorrhiza injection + 150 ml 5% dextrose solution. The observation group was given 80 ml ozagrel sodium + 100 ml 0.9% sodium chloride solution. The clinical efficacy of ozagrel sodium was evaluated by the therapeutic effect of two groups of patients, the neurological deficits before and after treatment, and the indexes of hemorheology (prothrombin time and fibrinogen) before and after treatment. Results The total effective rate of observation group was 96.08%, significantly higher than 84.31% of the control group, the difference was statistically significant (P <0.05). Pre-treatment prothrombin time, fibrinogen level, neurological deficiency score was no significant difference (P> 0.05). Prothrombin time in both groups was longer than before treatment, fibrinogen level was lower than before treatment, neurological deficiency score was lower than before treatment, the difference was statistically significant (P <0.05); and the observation group changes than the control group More significant differences were statistically significant (P <0.05). Conclusion Ozarec sodium is effective in the treatment of acute cerebral infarction, which can effectively improve the patients’ hemorheology and neurological function, which is beneficial to the prognosis of patients.